IRIS Institutional Research Information System - OPENBS Open Archive UniBS

BERRUTI, ALFREDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.737
EU - Europa 8.478
AS - Asia 5.918
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 16
AF - Africa 15
SA - Sud America 15
Totale 39.199
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.677
UA - Ucraina 2.684
CN - Cina 2.484
SG - Singapore 1.582
DE - Germania 1.181
IT - Italia 1.064
HK - Hong Kong 990
PL - Polonia 870
RU - Federazione Russa 574
TR - Turchia 518
IE - Irlanda 508
FI - Finlandia 472
GB - Regno Unito 433
FR - Francia 187
EE - Estonia 184
IN - India 110
CZ - Repubblica Ceca 105
VN - Vietnam 80
ID - Indonesia 76
SE - Svezia 71
CA - Canada 55
BE - Belgio 52
NL - Olanda 38
JP - Giappone 19
AU - Australia 18
EU - Europa 16
CH - Svizzera 14
KR - Corea 11
IR - Iran 9
AZ - Azerbaigian 8
PT - Portogallo 7
DK - Danimarca 5
MU - Mauritius 5
CL - Cile 4
GR - Grecia 4
TW - Taiwan 4
AR - Argentina 3
BR - Brasile 3
ES - Italia 3
IQ - Iraq 3
LA - Repubblica Popolare Democratica del Laos 3
LT - Lituania 3
MA - Marocco 3
RO - Romania 3
AL - Albania 2
BG - Bulgaria 2
CR - Costa Rica 2
GE - Georgia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
TH - Thailandia 2
ZA - Sudafrica 2
ZW - Zimbabwe 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BD - Bangladesh 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
CY - Cipro 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
FK - Isole Falkland (Malvinas) 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
MK - Macedonia 1
MX - Messico 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 39.199
Salva come PNG Salva come JPEG
Città #
Fairfield 4.232
Woodbridge 3.240
Houston 2.187
Ashburn 1.881
Jacksonville 1.876
Seattle 1.720
Cambridge 1.594
Ann Arbor 1.362
Singapore 1.342
Wilmington 1.342
Hong Kong 986
Princeton 879
Warsaw 870
Chandler 727
Beijing 548
New York 517
Nanjing 469
Dublin 466
Istanbul 457
Helsinki 393
Brescia 223
Dearborn 199
Des Moines 187
Moscow 187
Nanchang 186
Tallinn 184
San Diego 181
Shanghai 139
Shenyang 137
Changsha 134
Hebei 133
Boardman 132
Milan 112
Jinan 86
Tianjin 84
London 82
Brno 80
Dong Ket 80
Jakarta 75
Jiaxing 67
Munich 66
Los Angeles 64
Dalmine 60
Romola 57
Orange 56
Hangzhou 55
Brussels 51
Kocaeli 51
Verona 51
Kunming 48
San Francisco 43
West Jordan 38
Washington 35
Rome 34
Toronto 31
Ningbo 30
Zhengzhou 30
Lanzhou 26
Nürnberg 26
Naples 25
Kilburn 24
Olomouc 24
Haikou 23
Norwalk 23
Menlo Park 22
Guangzhou 21
Phoenix 21
Lancaster 20
Pune 20
San Mateo 19
Taizhou 19
Redwood City 17
Changchun 16
Augusta 15
Hefei 15
Leawood 15
North York 15
Acton 14
Chicago 13
Falkenstein 13
New Bedfont 13
Falls Church 12
Lappeenranta 12
Santa Clara 12
Chiswick 11
Fuzhou 11
Mumbai 10
Prescot 10
Walnut 10
Canberra 9
Espoo 9
Gumyojicho 9
Turin 9
Ardabil 8
Indiana 8
Melbourne 8
Napoli 8
Cazzago San Martino 7
Southwark 7
Vignate 7
Totale 31.212
Salva come PNG Salva come JPEG
Nome #
GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity 239
Adrenocortical carcinoma xenograft in zebrafish embryos as model to study the in vivo cytotoxicity of abiraterone acetate 217
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study 206
Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma 192
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 191
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy 178
Eight‐week interval in flushing and locking port‐a‐cath in cancer patients: A single‐institution experience and systematic review 177
Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures 177
Excess of second tumors in denosumab-treated patients: A metabolic hypothesis 171
Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review 169
Immunotherapy failure in adrenocortical cancer: where next? 165
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials 163
In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆ 157
Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy 154
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 154
Pros-IT CNR: an Italian prostate cancer monitoring project 152
IN VITRO ANTITUMOR ACTIVITY OF PROGESTERONE IN HUMAN ADRENOCORTICAL CARCINOMA 151
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case 151
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement 149
The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma 149
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 148
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma 146
Biological bases of radical prostatectomy in the management of prostate cancer patients with oligometastatic disease 145
Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis 144
Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma 144
Regression of advanced neuroendocrine tumors among patients receiving placebo 141
The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients 139
Should Adjuvant Weekly Paclitaxel Be Considered Less Efficacious Than Anthracyclines Plus Cyclophosphamide for Lower Risk Patients With Early-Stage Breast Cancer? 138
Palbociclib inhibits proliferation of human adrenocortical tumor cells 138
Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method 135
Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells 135
Osimertinib in EGFR Mutation–Positive Advanced NSCLC 133
Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis 132
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines 132
Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy 132
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells 132
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents 131
Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study 130
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity 130
Adjuvant bisphosphonates in patients with breast cancer: Does the potency matter? 129
Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy 129
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. 129
When should everolimus be administered in the natural history of pancreatic neuroendocrine tumors? 127
828PBONE METASTASES FROM RCC ARE NOT ALWAYS ASSOCIATED WITH A POOR PROGNOSIS 127
Exemestane with ovarian suppression in premenopausal breast cancer. 127
Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. 126
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. 126
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options 126
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer 124
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 124
Serum vitamin D and prostate cancer prognosis: The story continues 123
Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report 123
A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report 121
Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. 120
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports 119
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 118
Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance 118
Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer? 116
Acute myeloblastic leukemia associated with mediastinal nonseminomatous germ cell tumors. Report on two cases. 115
Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy worse radical cystectomy outcomes in frails 115
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. 114
Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases. 114
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement 114
IFN-α in advanced well-differentiated neuroendocrine tumors: The neglected drug? 114
Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice 113
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma. 112
Case-control study of the impact of adjuvant hormone therapy in prostate cancer patients on quality of life, anxiety and depression and self body image perception 111
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma 111
Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge. 111
The pathological diagnosis of neuroendocrine tumors: Common questions and tentative answers 111
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study 110
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature 110
Mediastinal non-seminomatous germ cell tumours: effectiveness of platinum, etoposide, bleomycin combination chemotherapy plus adjunctive surgery. 110
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 110
MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects 110
Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria 110
Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference 110
An unusual case of a well-differentiated neuroendocrine tumour of the ileum with peritoneal carcinomatosis: A case report 109
Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. 109
Molecular target agents in adrenocortical carcinoma: rationale and difficulties in trial design 109
Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature 109
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs) 109
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 109
Antineoplastic Activity of Artemisinin in Adrenocortical Carcinoma 109
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. 108
Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain. 107
Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. 107
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma 107
Combination chemotherapy in advanced adrenocortical carcinoma 107
Does nephrectomy during adrenalectomy for adrenal cancer improve oncological results? 106
Gonadal function in male patients with metastatic renal cell cancer treated with sunitinib: Effects of testosterone replacement on quality of life. 106
Follow-up and quality of life 106
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. 106
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): An European Network for the Study of Adrenal Tumor (ENSAT) study 106
Abiraterone and increased survival in metastatic prostate cancer 105
Systemic Therapy in Locally Advanced or Metastatic Adrenal Cancers: A Critical Appraisal and Clinical Trial Update 105
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. 104
Adjuvant mitotane treatment for adrenocortical carcinoma 104
Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. 104
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis 104
Totale 12.999
Salva come PNG Salva come JPEG
Categoria #
all - tutte 217.450
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 217.450
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.588 0 0 0 0 0 1.256 1.096 1.167 1.038 1.093 336 602
2020/20217.465 202 836 390 854 400 777 392 786 619 1.174 650 385
2021/20223.503 274 702 93 213 50 182 214 234 194 349 267 731
2022/20232.586 497 83 74 178 191 712 10 212 347 44 115 123
2023/20243.948 180 96 316 217 207 696 109 145 1.039 118 48 777
2024/20253.674 98 74 98 1.510 1.168 726 0 0 0 0 0 0
Totale 40.175